In8bio

INABNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$8.305 M

$0.84 -9.49%

Close of 6 Nov 2026

As of 6 Nov 2026, In8bio (INAB) has a market capitalization of $8.30M. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

—

Not reported

Earnings

-$19.4M

Loss-making

Shares outstanding

10,808,292

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 163 →

#149Passage BIOPASG$11.1M
#150Intensity TherapeuticsINTS$10.2M
#151In8bioINAB$8.30M
#152Senti BiosciencesSNTI$6.33M
#153AIM ImmunoTechAIM$6.14M

What if In8bio were worth as much as…

Open the what-if tool →

Gold $28.2T

$2,864,250

Per share 3,400,107× higher

Bitcoin $1.53T

$154,979.58

Per share 183,974× higher

Apple $5.02T

$508,783.49

Per share 603,969× higher

Or at a round number

$10.0M $20.0M $50.0M $100.0M

Where these numbers come from

Share counts and financials for In8bio are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.